About Soleno Therapeutics, Inc. - Common Stock (SLNO)
Soleno Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those associated with genetic and metabolic disorders. The company is committed to addressing significant unmet medical needs by advancing its proprietary treatment candidates through clinical trials. With an emphasis on leveraging cutting-edge science and research, Soleno aims to bring novel solutions to patients suffering from conditions like Prader-Willi syndrome, thereby enhancing their quality of life and overall health outcomes. Read More
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Levi & Korsinsky, LLP alerts investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of a pending securities class action. Class Period: March 26, 2025 through November 4, 2025. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive agreement to acquire Celeno Therapeutics (NASDAQ: SLNO). The all-cash transaction, valued at approximately $2.9 billion, underscores a strategic push
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most significant mid-cap success stories of the decade. Soleno Therapeutics (NASDAQ: SLNO) has transitioned from a struggling diagnostics firm to a commercial powerhouse, culminating in [...]
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.
BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium
LOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Soleno Therapeutics, Inc. (NASDAQ: SLNO) to Neurocrine Biosciences for $53.00 per share in cash.
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other gainers include Xiao-I Corp (NASDAQ: AIXI), Profusa Inc (NASDAQ: PFSA), and Soleno Therapeutics Inc (NASDAQ: SLNO). Losers include Intercont (Cayman) Ltd (NASDAQ: NCT), Visionary Holdings Inc (NASDAQ: GV), and PMGC Holdings Inc (NASDAQ: ELAB).
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2026 lead plaintiff deadline.
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO), if they purchased or otherwise acquired the Company’s shares between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.
